An observational study in Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO) and Diabetic Macular Edema (DME), sponsored by Hospital Hietzing. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Hospital Hietzing · Observational
The study compares the perceived treatment burden in patients undergoing intravitreal anti-VEGF treatment for either wet age related macular degeneration, macular edema after retinal vein occlusions or diabetic macular edema. This study is the first to the investigator's knowledge to compare treatment burden between all three patient groups, which also differ in age and socioeconomic circumstances. The results are of interest to all ophthalmologists who prescribe anti-VEGF treatments, as they show factors which can influence patient adherence und thus the efficacy of said therapies.
1,459 studies on the registry are indexed under Macular Degeneration; 238 are open to participants now.
This study's enrollment of 393 is above the median of 110 across 409 observational studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Hospital Hietzing is the lead sponsor of 15 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
393 patients (305 with nAMD, 55 with CME and 33 with DME)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with AMD receiving anti-VEGF treatment
Patients with DME receiving anti-VEGF treatment
Patients with RVO receiving anti-VEGF treatment
Severitiy of subjective treatment burden due to intravitreal anti-VEGF therapy assessed by questionnaire
The questionnaire was designed on the basis of the Longitudinal assessment of Adherence Factors to Intravitreal (anti-VEGF) Therapy (LAF-IVT) questionnaire. Patients were interviewed about their perceived treatment burden, their socioeconomic status, and demographic details. Different aspects of treatment burden were graden by the patients as "no", "little", "moderate", "great" or "extreme buden".
Time frame: From May 2023 to April 2024
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Apr 2024, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Hietzing